NCT06848348Phase 2Active not recruiting

Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain

Study sponsor: Dogwood Therapeutics Inc. · DWTX

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2026-12Estimated

Enrollment · participants240Estimated

Source updated2026-09-16Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-09-16 · 2 fields changed

Primary completion date changed

− Before

~~Jul 2026~~

+ After

Dec 2026

Recruitment status changed

− Before

~~Recruiting~~

+ After

Active not recruiting

Check registry source

Posted 2026-05-29 · 2 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Compare wording

− Before

Measure: ~~To explore the efficacy of Halneuron in the treatment of patients with Chemotherapy-Induced Neuropathic~~ Pain Measure: ~~To explore the~~ Safety ~~of Halneuron in the treatment of patients with Chemotherapy-Induced Neuropathic Pain~~

+ After

Measure: NRS Pain Measure: Safety Assessments

Planned enrollment increased by 40 participants

− Before

~~200 participants (planned)~~

+ After

240 participants (planned)

Check registry source

Study details

Conditions studied

Chemotherapy Induced Neuropathic Pain; Chemotherapy Induced Pain Neuropathy; Chemotherapy Induced Pain

Treatments or interventions studied

HalneuronDrug
PlaceboDrug
Halneuron (Open Label Extension)Drug

Primary outcomes · main study measures

Read the study measures

measure: NRS Pain; description: Change from Baseline in the weekly average of daily 24-hour pain intensity scores analyzed by percentage of responders among patients treated with Halneuron compared to Placebo; timeFrame: From enrollment to end of study at 4 weeks; measure: Safety Assessments; description: Incidence of serious adverse events (SAEs), adverse events (AEs) and Adverse Events of Special Interests (AESIs); timeFrame: From enrollment to end of study at 4 weeks

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history